Daling Zhu Selected Research

Hydroxyeicosatetraenoic Acids (HETE)

10/2018	Exosomal 15-LO2 mediates hypoxia-induced pulmonary artery hypertension in vivo and in vitro.
1/2018	15-Lipoxygenase/15-hydroxyeicosanoid and activator protein 1 contribute to hypoxia-induced pulmonary artery smooth muscle cells phenotype alteration.
1/2018	MMP-2 and MMP-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells.
1/2018	15-Lipoxygenase-2/15(S)-hydroxyeicosatetraenoic acid regulates cell proliferation and metastasis via the STAT3 pathway in lung adenocarcinoma.
9/2015	15-Lipoxygenase and 15-hydroxyeicosatetraenoic acid regulate intravascular thrombosis in pulmonary hypertension.
7/2015	15-Lipoxygenase promotes chronic hypoxia-induced phenotype changes of PASMCs via positive feedback-loop of BMP4.
1/2015	Modulation of Pulmonary Vascular Remodeling in Hypoxia: Role of 15-LOX-2/15-HETE-MAPKs Pathway.
8/2014	NFATc3 pathway participates in the process that 15-LO/15-HETE protects pulmonary artery smooth muscle cells against apoptosis during hypoxia.
2/2014	15-LO/15-HETE mediated vascular adventitia fibrosis via p38 MAPK-dependent TGF-β.
1/2014	Enhancement of the HIF-1α/15-LO/15-HETE axis promotes hypoxia-induced endothelial proliferation in preeclamptic pregnancy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daling Zhu Research Topics

Disease

73	Hypoxia (Hypoxemia) 02/2024 - 05/2003
30	Pulmonary Hypertension 02/2024 - 02/2011
22	Vascular Remodeling 02/2024 - 02/2002
17	Pulmonary Arterial Hypertension 05/2019 - 01/2010
11	Neoplasms (Cancer) 11/2020 - 03/2008
6	Hypertension (High Blood Pressure) 01/2016 - 01/2008
5	Wounds and Injuries (Trauma) 11/2019 - 11/2012
4	Inflammation (Inflammations) 01/2020 - 01/2007
4	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 11/2009
4	Hypertrophy 01/2019 - 10/2011
3	Fibrosis (Cirrhosis) 01/2020 - 07/2003
3	Neoplasm Metastasis (Metastasis) 01/2018 - 06/2013
3	Premature Birth (Birth, Premature) 06/2016 - 07/2014
2	Vascular Calcification 12/2020 - 01/2018
2	Hepatocellular Carcinoma (Hepatoma) 11/2020 - 06/2013
2	Lung Injury 01/2020 - 04/2011
2	Right Ventricular Hypertrophy 05/2019 - 06/2016
2	Carcinogenesis 01/2019 - 01/2016
2	Breast Neoplasms (Breast Cancer) 01/2018 - 10/2016
2	Osteosarcoma (Osteogenic Sarcoma) 01/2017 - 01/2016
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2016 - 01/2016
2	Pathologic Processes 08/2013 - 12/2012
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2023
1	Necrosis 01/2020
1	Genomic Instability 01/2020
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020
1	Coronary Disease (Coronary Heart Disease) 01/2020
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 10/2019

Drug/Important Bio-Agent (IBA)

32	AcidsIBA 01/2018 - 07/2003
30	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 01/2018 - 05/2003
29	15-hydroxy-5,8,11,13-eicosatetraenoic acidIBA 01/2018 - 05/2003
20	Hydroxyeicosatetraenoic Acids (HETE)IBA 10/2018 - 06/2008
18	Proteins (Proteins, Gene)FDA Link 02/2024 - 01/2009
13	Small Interfering RNA (siRNA)IBA 11/2020 - 01/2010
10	Arachidonic Acid (Vitamin F)IBA 04/2014 - 06/2008
9	Bromodeoxyuridine (BrdU)IBA 12/2020 - 10/2011
8	Circular RNAIBA 01/2023 - 01/2019
6	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2019 - 08/2012
5	Long Noncoding RNAIBA 10/2022 - 12/2015
4	MonocrotalineIBA 02/2024 - 01/2013
4	CalciumIBA 12/2020 - 08/2010
4	biliverdin reductaseIBA 01/2018 - 08/2013
4	p38 Mitogen-Activated Protein KinasesIBA 01/2018 - 02/2014
4	Vasodilator Agents (Vasodilators)IBA 01/2016 - 01/2008
4	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 11/2012
3	Messenger RNA (mRNA)IBA 02/2024 - 01/2009
3	Phosphotransferases (Kinase)IBA 01/2020 - 02/2011
3	EnzymesIBA 01/2018 - 05/2013
3	BilirubinIBA 01/2018 - 08/2013
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 08/2012
3	Masoprocol (Actinex)FDA Link 09/2015 - 01/2010
3	Oxygen (Dioxygen)IBA 05/2013 - 04/2011
2	Semaxinib (SU5416)IBA 02/2024 - 09/2015
2	RNA (Ribonucleic Acid)IBA 01/2023 - 10/2020
2	Beclin-1IBA 01/2023 - 01/2017
2	Peptides (Polypeptides)IBA 06/2022 - 01/2021
2	UbiquitinIBA 01/2022 - 10/2018
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2020 - 06/2013
2	Caspase 3 (Caspase-3)IBA 11/2019 - 01/2018
2	DAPIIBA 11/2019 - 05/2009
2	Cyclophilin AIBA 03/2019 - 01/2017
2	AntioxidantsIBA 03/2019 - 01/2018
2	MicroRNAs (MicroRNA)IBA 01/2019 - 05/2012
2	Biliverdine (Biliverdin)IBA 01/2018 - 04/2011
2	TubulinIBA 01/2018 - 07/2015
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2018 - 01/2015
2	Cyclin D1IBA 01/2018 - 01/2010
2	Platelet-Derived Growth FactorIBA 10/2016 - 10/2012
2	Imatinib Mesylate (Gleevec)FDA Link 10/2016 - 10/2012
2	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2016 - 01/2016
2	Dynamins (Dynamin)IBA 07/2016 - 09/2015
2	Transforming Growth Factor beta1 (TGF beta 1)IBA 01/2016 - 07/2012
2	Cyclin AIBA 07/2015 - 11/2012
2	PPAR gammaIBA 01/2015 - 08/2012
2	Annexin A5IBA 08/2014 - 05/2009
2	15-hydroxyprostaglandin dehydrogenaseIBA 07/2014 - 07/2014
2	CollagenIBA 02/2014 - 02/2002
2	IsoenzymesIBA 01/2012 - 01/2009
2	Estrogen Receptor alphaIBA 11/2009 - 01/2007
1	Presenilin-1IBA 02/2024
1	Glycerol KinaseIBA 01/2023
1	SirtuinsIBA 12/2020
1	Alkaline PhosphataseIBA 12/2020
1	Alizarin Red SIBA 12/2020
1	Type I Tumor Necrosis Factor ReceptorsIBA 01/2020
1	Molecular Chaperones (Chaperone, Molecular)IBA 01/2020
1	Caspase 8 (Caspase-8)IBA 01/2020
1	Piwi-Interacting RNAIBA 01/2020
1	LipopolysaccharidesIBA 01/2020
1	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2020
1	Poly TIBA 01/2020
1	B7-H1 AntigenIBA 01/2020
1	Circulating MicroRNAIBA 01/2020
1	Pyridinolcarbamate (P23)IBA 01/2020
1	Fibrillar CollagensIBA 01/2020
1	thiazolyl blueIBA 11/2019
1	FlavonoidsIBA 10/2019
1	puerarinIBA 10/2019
1	dacomitinibIBA 05/2019

Therapy/Procedure

5	Therapeutics 07/2015 - 05/2009